Hypertension is commonly associated with cardiac arrhythmias in patients with and without concomitant cardiovascular disease. Experimental and epidemiological studies have demonstrated potential links between hypertension and atrial and ventricular arrhythmias, although the underlying pathophysiological mechanism remains unclear. Nonetheless, the importance of hypertension as a cause of atrial and ventricular arrhythmias is not well recognized. In particular, the occurrence of left ventricular hypertrophy is a strong predictor for the development of AF, ventricular ectopy and sudden cardiac death. Recent prospective clinical trials reveal that antihypertensive therapy may delay or prevent the occurrence of cardiac arrhythmias and sudden cardiac death in patients with hypertension. Although antihypertensive agents that block the renin-angiotensin-aldosterone system appear to protect against cardiac arrhythmias, this needs to be confirmed by current ongoing clinical trials.
Introduction
Concomitant cardiac arrhythmias are commonly seen in patients with hypertension, although the mechanism of this association is unclear. The contribution of hypertension to the development of atrial and ventricular arrhythmias is unrecognized and thus undertreated. Recent clinical trials have demonstrated the possible preventive role of antihypertensive agents, in particular those that induce blockade of the renin-angiotensin-aldosterone system (RAAS). The aim of this paper is to review the epidemiology, underlying mechanisms and clinical implications of atrial and ventricular arrhythmias in hypertensive patients. We searched MEDLINE using the following terms individually and/or in combination: 'atrial fibrillation (AF)', 'left ventricular hypertrophy (LVH)', 'hypertension', 'ventricular arrhythmias' and 'sudden cardiac death (SCD)'. In addition, abstracts from international cardiovascular meetings were studied to identify unpublished studies.
Epidemiology

Atrial fibrillation
Atrial fibrillation is the most common sustained arrhythmia in adults and is associated with an increased risk for cardiovascular morbidity, mortality and stroke.
1, 2 The incidence of AF increases with age; a prevalence of 0.1% in adults younger than 55 years increases to 9% in adults older than 80 years. 3, 4 In the Framingham Heart Study, the lifetime risk for developing AF was one in four in men and women aged 40 years or above. 5 Among different risk factors, hypertension is one of the important independent risk factors for the development of AF. 6 In the Cardiovascular Health Study of subjects older than 65 years of age, the risk for developing new-onset AF was higher in hypertensive patients: the relative risk was 1.11 after adjustment for age and other covariates. 7 The Framingham Study cohort 8 also demonstrated that hypertension and diabetes were the only cardiovascular risk factors that were responsible for the development of new-onset AF. Hypertension was responsible for more AF in the population (14%) than any other risk factor due to its high prevalence. After adjusting for age, hypertension increased the risk of AF by 80% in female patients and 70% in male patients. In addition, evidence of LVH on ECG was associated with at least a threefold increased risk for AF. In the Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) Study, age and left ventricular (LV) mass as measured by echocardiogram were independent predictors for new-onset AF after a mean follow-up period of 5.3 years. 9 The high prevalence of coexistent hypertension and AF is also reflected by the high proportion of hypertensive patients who require antihypertensive treatment (470%) and who are participating in major clinical trials on AF, such as the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study 10 and the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF III) Study.
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Ventricular arrhythmia
In patients with hypertension, the most important determinant for the occurrence of ventricular arrhythmia is the presence of LVH. Several studies have shown that hypertensive patients with LVH have an increased frequency of premature ventricular ectopic beats and ventricular arrhythmias. [12] [13] [14] [15] In the Framingham Heart Study, echocardiographic evidence of LVH was associated with ventricular arrhythmia independent of conventional cardiovascular risk factors. 12 In untreated hypertensive patients, non-sustained ventricular arrhythmia was observed in up to 5% of patients during 24-h Holter monitoring. 14 
Sudden cardiac death
The presence of LVH is strongly correlated with SCD, although a direct causal relationship has not been identified. 16, 17 In the Framingham Heart Study, 17 an incremental increase in LV mass by 50 g m À2 conferred a 45% higher risk of SCD in hypertensive subjects aged 440 years. Increased LV mass and LVH were also associated with a long-term risk of sudden death. The presence of asymptomatic complex or frequent ventricular arrhythmia in the absence of coronary artery disease was also associated with a 62% increase in mortality. 18 Electrophysiological studies in hypertensive patients with LVH have nonetheless yielded conflicting results. 19, 20 In symptomatic hypertensive patients, the presence of LVH increased susceptibility to the development of malignant ventricular arrhythmia during programmed ventricular stimulation. 20 
Pathophysiology
The development of atrial and ventricular arrhythmias in hypertensive patients and patients with LVH appears to be complex. It is, nonetheless, clearly evident that hypertension and LVH exert a robust proarrhythmic effect on the heart.
Atrial fibrillation
In patients with hypertension, several mechanisms may contribute to the development of AF (Figure 1 ).
Renin-angiotensin-aldosterone system. It has been well demonstrated that activation of the RAAS occurs in patients with hypertension 21 and is strongly implicated in the development of AF. 22 Evidence is accumulating that explains the link between RAAS and AF: there are two receptor subtypes that act as binding sites for angiotensin II, namely AT1 and AT2. Most of the known effects of angiotensin II in adult tissue are attributable to the actions AT1 receptor and acts antagonistically by the action of AT2. 23 In addition to its known physiological effects (vasoconstriction, aldosterone and vasopressin release, sodium and water retention and sympathetic facilitation), AT1 also induces atrial myocyte hypertrophy and fibrosis that predispose an individual to development of AF. 24 Upregulation of the AT1 receptor in the left atrium in patients with AF, but not the AT2 receptor, has been demonstrated. 25 In contrast, there is downregulation of AT1 and upregulation of AT2 in the right atrium. 26 Angiotensin II is known to induce proliferation of fibroblasts and extracellular matrix protein accumulation via activation of the mitogenactivated protein kinases. 27 Experimental studies show that inhibition of this angiotensin II pathway attenuates the formation of fibrosis and diminishes the incidence of AF. 28 In a hypertensive rat heart model, the degree of atrial fibrosis correlated with the susceptibility for development of atrial tachycardia. 29 Structural remodelling of the atria related to the activation of RAAS can thus contribute to the development of AF in hypertension.
In an animal model, rapid atrial pacing resulted in atrial electrical remodelling, characterized by shortening of the atrial effective refractory period and loss of the normal rate adaptation of refractoriness. 30 Blockade of RAAS can prevent the development of electrical remodelling for short (3 h), 31 but not long periods of time (1-5 weeks). 32 It has been postulated that an increased angiotensin II level is proarrhythmic due to increased intracellular calcium. The latter is due to increased intake of extracellular calcium and increased release from the sarcoplasmic reticulum through the activation of membrane L-type calcium channels or phosphatidylinositolphospholipase C pathways. 33, 34 In addition, activation of RAAS may lead to inflammation: this has also been implicated in the pathogenesis of AF. 35 Experimental studies have shown that angiotensin II possesses proinflammatory properties, inducing the production of reactive oxygen species, inflammatory cytokines and adhesion molecules. 36 In accordance with this observation, angiotensin II receptor blockade has been shown to significantly reduce multiple markers of inflammation (C-reactive protein, TNF-a, IL-6 and monocyte chemotactic protein-1) in hypertensive patients. 37 Haemodynamic changes in atria. The excessive increase in afterload imposed by hypertension will lead to cardiac compensation with progressive thickening of the LV wall and consequent LVH. Histologically, LVH is characterized by hypertrophy of existing cardiomyocytes surrounded by connective tissue with cardiac fibrosis. 38, 39 In addition to the established relationship between LVH and adverse cardiovascular events, 40 previous studies have shown that the presence of LVH may also predispose to the development of cardiac arrhythmia. 8, 12 Increased stiffness of the LV after LVH will inevitably lead to diastolic dysfunction that subsequently contributes to the occurrence of AF. 41, 42 Long-standing increased LA (left atrial) pressure due to impaired LV relaxation in the hypertensive heart will also eventually lead to LA enlargement. In the Framingham Heart Study, 43 both the duration of elevated blood pressure and the level of systolic blood pressure were associated with the development of LA dilatation. The consequent distention and stretching of the atria related to hypertension can alter atrial electrophysiological properties, including shortening of the effective refractory period and increased dispersion of refractoriness with subsequent increased vulnerability to AF. 44, 45 Ventricular arrhythmia The presence of LVH is the most important determinant for the occurrence of ventricular arrhythmia and/or SCD in hypertensive patients. The pattern of LVH may also have important implications for the prognosis and type of cardiovascular complications in hypertensive patients. Previous studies have shown that hypertensive patients with chronic LVH may be more prone to severe ventricular arrhythmias, whereas concentric hypertrophy is more related to ischaemic events that result from abnormal coronary autoregulation. 46 As shown in Figure 2 , several mechanisms have been proposed to explain the relationship between the presence of LVH and ventricular arrhythmias in hypertension.
Electrophysiology disturbance. It has been well established that prolongation and dispersion of LV repolarization are associated with an increased risk of ventricular tachyarrhythmias including torsade de pointe and ventricular tachycardia. One of the salient features in myocardial hypertrophy is the presence of early after-depolarization and triggered activity that may increase the dispersion of repolarization to cause sustained arrhythmia. 47 Indeed, prolongation of the QT interval, similar to a pharmacologically induced proarrhythmic effect, has also been observed in LVH. 48 In addition, QT dispersion that represents the degree of repolarization inhomogeneity in the heart is associated with LVH 49 and hypertension. 50 At a cellular level, structural remodelling induced by hypertension is associated with impaired cell-cell communication at the gap junction and increased susceptibility to ventricular arrhythmia induced by hypokalaemia in an animal model. 51 Nonetheless, vulnerability to ventricular fibrillation is not related to abnormal calcium channel handling. 52 Although there remains much speculation about the underlying mechanism, it is established that electrical instability induced by hypertension and LVH is an important mechanism in inducing ventricular arrhythmia.
Myocardial ischaemia. Hypertension and LVH may also cause myocardial ischaemia through other mechanisms. Hypertrophy of the LV will lead to a mismatch between myocardial blood supply and oxygen consumption. In hypertensive patients with or without LVH, decreased diastolic coronary blood flow may cause subendocardial ischaemia. 53 Microvascular dysfunction with myocardial ischaemia has been reported in both prehypertensive and hypertensive patients even in the absence of LVH, 54, 55 suggesting that impaired myocardial perfusion may develop in the early stage of hypertension. The presence of myocardial ischaemia may trigger the onset of ventricular arrhythmia and SCD in patients with hypertension.
Myocardial fibrosis. Experimental studies have shown that pressure overloading of the LV is associated with increased collagen synthesis and degradation. 56 Excessive accumulation of fibrillar collagen is a characteristic feature of hypertensive heart disease. The increased myocardial fibrosis may lead to distortion of the tissue structure and increased stiffness of the myocardium to cause LV diastolic dysfunction. 57 These structural changes in the myocardium related to increased myocardium fibrosis can lead to nonhomogeneous propagation of electrical impulses and give rise to ventricular arrhythmias due to re-entry.
Neuroendocrine effects. Excessive activation of the sympathetic nervous system and the RAAS has been demonstrated in the pathogenesis of essential hypertension as well as in the development of LVH. 22, 58 Sympathetic activation has been shown to exert a direct proarrhythmic effect that may lead to ventricular arrhythmia and SCD. 59, 60 No direct link has been demonstrated between angiotensin II and ventricular arrhythmias. Nevertheless, angiotensin II can lead to LVH by increasing blood pressure or possibly via direct trophic actions on the heart 61 that subsequently increase vulnerability to ventricular arrhythmias and SCD.
Clinical implication
While the pathophysiology of cardiac arrhythmias in hypertension is unknown, the identification of a close link between blood pressure control and the presence of LVH with the development of cardiac arrhythmias offers possibilities for therapeutic intervention and prevention of AF, ventricular arrhythmias and SCD in hypertensive patients by means of blood pressure control and LVH regression. Existing evidence demonstrates that optimal blood pressure control and regression of LVH with antihypertensive therapy are associated with improved LV diastolic function, reduced LA size and changes in plasma catecholamines that may contribute to the prevention of cardiac arrhythmias. [62] [63] [64] Among different classes of antihypertensive agents, angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) appear to have better efficacy in terms of reduction of cardiac arrhythmias. 65 Blockade of RAAS has been proven to regress LVH and likely explains, in part, its protective effect in arrhythmias. The regression of LVH by ARB in patients with hypertension is independent of its blood pressure-lowering effect. 66 Furthermore, regression of hypertensive LVH is seen independently of lowering blood pressure. 67 Experimental studies have shown that blockade of ARB or ACEI attenuates atrial structural remodelling with fibrosis and atrial electrical remodelling, both factors that predispose to AF. 68, 69 Atrial fibrillation The effect of specific class of antihypertensive agents on the prevention of AF remains unclear. Retrospective studies 70 suggest that blockade of RAAS with ACEI in patients with hypertension reduces the relative risk of developing AF by 15% compared with CCB (calcium channel blocker). Patients with a prior history of AF appear to derive greater benefit from ACEI-based therapy in the prevention of AF. 66, 71, 72 Emerging data from the analysis of large prospective clinical studies also demonstrate the beneficial effects of blockade of RAAS in preventing AF in patients with hypertension. In the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study, ARB-based therapy (losartan) was associated with a 33% reduction in the incidence of AF and with a significant reduction in the incidence of subsequent stroke compared with b-blocker-based therapy (atenolol). 73 Similarly, in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial, ARB-based therapy (valsartan) had a 16% risk reduction in the incidence of AF compared with CCB-based therapy (amlodipine) after adjustment for confounding covariates. 71 In patients with concomitant hypertension and AF, ARB-based therapy (losartan) in combination with amiodarone was also more effective than CCB-based therapy (amlodipine) in preventing the recurrence of AF. 74 Nevertheless, meta-analysis of three major clinical trials (Captopril Prevention Project (CAPP), Swedish Trial in Old Patients with Hypertension-2 (STOP-H-2) and LIFE) including 12 114 patients with hypertension have failed to show a consistent reduction in AF with ACEI and ARB. 75 In addition to the blockade of RAAS with specific agents, both the blood pressurelowering effect and LVH regression of different antihypertensive agents make an important contribution to the prevention of AF. Recent analysis of data from the LIFE Study reveals that regression of electrocardiographic LVH during antihypertensive therapy was a major determinant for the prevention of AF, independent of the blood pressure lowering and the effect of ARB-based therapy. 72 Several prospective clinical studies (Table 1) are currently underway to address whether blockade of RAAS with ARB can prevent AF in patients with hypertension. The GISSI-AF Trial intends to examine the incidence of recurrent AF in a broad spectrum of cardiovascular risk patients including hypertension (n ¼ 1402) with valsartan versus placebo. 76 The Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling (I-PACE) Trial investigates the effect of irbesartan versus placebo in hypertensive patients with atrial tachyarrhythmias and implanted pacemakers. 77 The
Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events-I (ACTIVE-I) Trial assesses the effect of irbesartan versus placebo on the prevention of AF recurrence in patients with multiple cardiovascular risk factors and paroxysmal AF. 78 The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II Study) compares the effect of candesartan versus amlodipine for treatment of paroxysmal AF in patients with hypertension. 79 The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) Study investigates the efficacy of telmisartan, ramipril and combination therapy with telmisartan plus ramipril for reducing cardiovascular events, including AF in high-risk patients with controlled blood pressure. This study will provide important data on the potential incremental benefit of ACEI, ARB or both in preventing AF, independent of blood pressure lowering. 80 Finally, data concerning the potential effect of blockade of RAAS with aldosterone antagonists, such as spironolactone and eplerenone, for AF prevention in patients with hypertension are lacking. Further studies are needed to discern their association.
In regard to the treatment of AF in patients with hypertension, recent randomized trials have demonstrated similar clinical outcomes with rate-control and rhythm-control strategy, in terms of quality of life, stroke and mortality. [81] [82] [83] [84] These studies highlighted the low clinical efficacy of current antiarrhythmic agents to maintain sinus rhythm. This probably contributes to the stroke risk associated with rhythm control, especially in a high-risk hypertensive population. Therefore, in patients with hypertension and AF, the use of oral anticoagulant with warfarin should be considered for stroke prevention, irrespective of whether rate or rhythmcontrol strategy is used. 85 However, one of the major drawbacks of warfarin is the potential of increasing risk of haemorrhagic events. Therefore, the risk and benefit of warfarin therapy must be assessed individually for every patient. Compared with warfarin, aspirin is less effective in preventing stroke, and can only be recommended for patients who refuse or cannot safely take warfarin.
In those patients who need ventricular rate control, either b-blocker and/or a rate-limiting CCBs (diltiazem or verapmail) is a suitable initial choice of therapy in patients with hypertension. In patients with impaired LV function or LVH, the use of Class I and III antiarrhythmic agents is associated with an increase risk of proarrhythmia. Therefore, only amiodarone is recommended for rhythm control in patients with hypertension and LVH. 86 Until recently, the only data available on the impact of LVH regression and SCD came from LIFE. 87 In this study, the presence of regression of electrocardiographic LVH during antihypertensive therapy was associated with a 30% lower risk of SCD independent of blood pressure lowering and other known predictors for SCD. Furthermore, ARBbased therapy seemed to provide similar cardioprotection against SCD compared with b-blocker-based therapy. Although b-blocker has been shown to prevent SCD in patients with heart failure and myocardial infarction, 88, 89 case-control studies in patients with hypertension suggested that b-blocker was associated with an increased risk of SCD. 90 Similarly, the use of thiazide diuretic has been linked to an increased risk of cardiac arrhythmia. Siscovick et al. 91 had shown a dose-dependent increase in SCD in patients treated with thiazide diuretic. Although the exact mechanism remains unknown, it is possible that undetected hypokalaemia related to the use of high-dose diuretic can lead to ventricular arrhythmia including torsade de pointes. Indeed, the use of non-potassium-sparing diuretic was associated with a twofold increased risk of SCD compared with the use of potassiumsparing diuretic. 90 In contrast, recent studies demonstrated that candesartan-based and amlodipine-based regimens produced no statistical differences in the risk of SCD in high-risk hypertensive patients. 92 Nevertheless, future studies are needed to confirm whether alleviation of LV structural remodelling related to hypertension by LVH regression with different classes of antihypertensive agents can prevent ventricular arrhythmias and SCD.
In hypertensive patients with asymptomatic and non-sustained ventricular arrhythmias, there is no role for prophylactic use of antiarrhythmic agents. In these hypertensive patients, especially those with LVH or LV dysfunction and those who suffered from sustained and symptomatic ventricular tachycardia not related to a reversible causes, implantable cardioverter defibrillator should be considered for prevention of SCD.
Conclusions
Experimental and epidemiological studies have established a close link between hypertension, LVH and cardiac arrhythmias. In patients with hypertension, alteration of cardiac haemodynamic, structural and electrophysiological properties imposed by hypertension and LVH can contribute to the development of AF, ventricular arrhythmias and SCD. Effective antihypertensive therapy with different agents to lower blood pressure and, more importantly, to regress LVH can prevent AF and SCD. Whether the use of ACEI or ARB to block the RAAS is more effective in preventing cardiac arrhythmias in patients with hypertension remains to be determined by current ongoing clinical trials.
